Two-year treatment with oral contraceptives in hyperprolactinemic patients

Giovanna Testa, Walter Vegetti, Tiziano Motta, Federica Alagna, Diana Bianchedi, Clelia Carlucci, Massimiliano Bianchi, Fabio Parazzini, Pier Giorgio Crosignani

Research output: Contribution to journalArticle


The aim of this prospective study was the follow-up for 2 years in symptoms, serum prolactin (PRL) levels, and radiological aspects of a group of young patients using oral contraceptives (OC) with hyperprolactinemia. A total of 16 hyperprolactinemic women (eight with idiopathic hyperprolactinemia and eight with pituitary microadenoma) who started OC use were admitted in the study. After 2 years of OC use, the assessable patients showed a nonsignificant decrease in plasma PRL level (26.8 ± 29.4 μg/mL, range 4.2-97.1 μg/mL vs 56.3 ± 31.5 μg/mL, range 23.5-144 μg/mL). No patient experienced any radiological changes during OC treatment. In conclusion, although the number of observations is limited, the data suggest that after 2 years of follow-up, no harmful effect of OC use was observed in these patients.

Original languageEnglish
Pages (from-to)69-73
Number of pages5
Issue number2
Publication statusPublished - Aug 1998


  • Hyperprolactinemia
  • Microadenoma
  • Oral contraception
  • Pituitary
  • Prospective study

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Two-year treatment with oral contraceptives in hyperprolactinemic patients'. Together they form a unique fingerprint.

  • Cite this

    Testa, G., Vegetti, W., Motta, T., Alagna, F., Bianchedi, D., Carlucci, C., Bianchi, M., Parazzini, F., & Crosignani, P. G. (1998). Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception, 58(2), 69-73.